What happens to Celgene (CELG) if the proposed $74 billion acquisition by Bristol-Myers Squibb (BMY) dies?
“That would be a total nightmare, a worst-case scenario for Celgene, so right now, the directors on its board are doing everything they can to prevent the deal from unraveling,” said Jason Aryeh, founder and partner at JALAA Equities, an activist hedge fund.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
why panic,though i have a fair stake in celgene,and welcome the deal,our pipeline ought to suffice for the future.If not,than what is all the hype about Bristol Myers looking toward the future via the celgene pipeline.It the deal goes south,why should Celgene given their future drug prospects.These scare tactics are just short term profit driven behaviors.